Hematology Analyzer
Closed Pre-Solicitation Posted
- Solicitation number
- FA483024Q0076
- Agency
-
Air Combat Command
Air Force, Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- Not on record
- PSC
- Not on record
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of the Air Force Air Combat Command is seeking to procure a Hematology Analyzer to be used by the 23 Medical Group Laboratory. The analyzer must have the capability to perform closed and open tube sampling, provide a 6-part differential, fully automated reticulocyte analysis, and reticulocyte hemoglobin measurement. It must be FDA approved and offer features such as reportable Immature Granulocyte (IG) as part of the routine results, automated and expanded measures of hematopoiesis, and a quality assurance program to document and maintain analyzer peer comparison data. The requested analyzer must fit within specific size and weight limitations. Responses are due by September 24, 2024.
This procurement is not set-aside for any specific category of business. The pre-solicitation notice does not mention any potential incumbents or current contractors. The notice does not provide any information about the anticipated award value or budget range. The required quantity is one Hematology Analyzer.
Notice text
23 Medical Group Laboratory is requesting the purchase of 1 Hematology Analyzer.
Analyzer needs to perform closed and open tube sampling. Should have a fully integrated IPU with LCD touchscreen, intuitive on-board software. Compact analyzer needs to be Federal Drug Administration (FDA) approved to provide a 6-part differential, fully automated reticulocyte analysis, and reticulocyte hemoglobin measurement. Requested equipment/analyzer has fluorescent flow cytometry for white blood cell (WBC), WBC differential, nucleated red blood cell (NRBC), and reticulocyte identification and reagent management technology, which is standard with the reagent system.
The analyzer must also offer clinical and operational advantages that provide additional information and reduce the need for manual confirmatory differentials. Among these should be reportable Immature Granulocyte (IG, the six-part differential with a maximum of 25 L per sample) as part of the routine results, WITHOUT additional reagents needed, additional cost, or additional work by the operator. The instrument must also have automated and expanded measures of hematopoiesis to accelerate the identification and enumeration of reportable immature cell indices to include Immature Granulocytes (IG) - the number of metamyelocytes, myelocytes, and promyelocytes. The analyzer must measure hemoglobin in a separate chamber to remove WBC interference, using a reagent to help reduce interference from lipemia and abnormal proteins.
MUST include a quality assurance program to Instantly document and maintain Q.A. history for analyzer peer comparison data across multiple sites with a single login. On demand and flexible reporting options Ability to manage QC Accessible 24/7 lot-to-date reporting Online QC record storage for up to 2 years. Single login access for reports across multi-analyzer sites Comprehensive support available 24/7
Requested analyzer must fit in limited space and be no larger than height - 17", width - 18", depth - 18" and weight of NO MORE than 80 lbs.
This post is seeking sources ONLY.
Requirement meets the definition of a commercial item as defined in FAR 2.101."Commercial item" paragraph (6) states that services of a type offered and sold competitively in substantial quantities in the commercial marketplace based on established catalog or market prices for specific tasks performed or specific outcomes to be achieved and under standard commercial terms and conditions.
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity